… and cut funding to the research project.
https://www.nytimes.com/2024/12/25/opinion/ozempic-weight-loss-pfizer-diabetes.html
{{ In 1990, reviewing Flier’s team’s results, Pfizer gave the researchers one year to develop a non-injectable delivery system that might justify the expense of developing an alternative to insulin — a quixotically short timeline that effectively doomed the project, forestalling work on some of the obvious next research steps.
From that point, Flier guesses that the next major breakthrough, identifying the enzyme that naturally degrades GLP-1 in minutes in order to develop a mechanism to counteract or stall that effect, would have taken only a few months. But “it wasn’t a sure thing,” he acknowledges, and “it’s almost always longer than you would imagine.” It took 15 years for Exendin-4, which was isolated from Gila monster venom in 1990, to make it to market as the first GLP-1 therapy, Exenatide. The original patent Flier and his colleagues licensed from Massachusetts General, which eventually passed to Novo Nordisk, didn’t yield an F.D.A.-approved drug until 2010. }}
intercst